Sugi Predict

Sugi Predict / Compounds / SCHEMBL1470130

SCHEMBL1470130

SCHEMBL1470130

NC(=O)c1ccc(N)c([N+](=O)[O-])c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.74
▸ PARP1 P09874 1/20 0.67
▸ TDP1 Q9NUW8 3/20 0.58
▸ TSHR P16473 3/20 0.58
▸ MAPT P10636 3/20 0.58
▸ ALDH1A1 P00352 3/20 0.58
▸ MEN1 O00255 2/20 0.58
▸ KMT2A Q03164 2/20 0.58
▸ CYP3A4 P08684 2/20 0.58
▸ POLB P06746 1/20 0.58
▸ ALOX15 P16050 1/20 0.58
▸ GAA P10253 2/20 0.55
▸ PKM P14618 1/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ SMN1; SMN2 Q16637 2/20 0.53
▸ CRHBP P24387 1/20 0.50
▸ CRHR2 Q13324 1/20 0.50
▸ ATM Q13315 1/20 0.50
▸ CTPS1 P17812 1/20 0.50
▸ CASP6 P55212 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6369255 0.98 LMNA (0.72) LMNAPARP1TDP1TSHRMAPT
SCHEMBL31174170 0.87 LMNA (0.77) LMNAPARP1TDP1TSHRMAPT
SCHEMBL865520 0.87 LMNA (0.77) LMNAPARP1TDP1TSHRMAPT
SCHEMBL11493618 0.85 MAPK1 (0.66) LMNAPARP1TDP1TSHRMAPT
SCHEMBL1162258 0.85 LMNA (1.00) LMNATDP1TSHRMAPTALDH1A1
SCHEMBL441296 0.85 LMNA (1.00) LMNATDP1TSHRMAPTALDH1A1
SCHEMBL1254186 0.85 PARP1 (0.71) LMNAPARP1TSHRMAPTALDH1A1
SCHEMBL263311 0.84 LMNA (0.72) LMNATDP1TSHRMAPTALDH1A1
SCHEMBL1966655 0.84 LMNA (0.72) LMNAPARP1TDP1TSHRMAPT
SCHEMBL31958588 0.84 LMNA (0.72) LMNAPARP1TDP1TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1590332-B1 A PROCESS FOR THE SYNTHESIS OF BISBENZIMIDAZOLES AND THEIR DERIVATIVES. UNIV DELHI (IN) 2011-04-27 — — EP claimed
US-20240018129-A1 COMPOUNDS AS PU. 1 INHIBITORS S-Infinity Pharmaceuticals (CN) 2024-01-18 — — US disclosed
US-20240018129-A1 COMPOUNDS AS PU. 1 INHIBITORS S-Infinity Pharmaceuticals (CN) 2024-01-18 — — US disclosed
CN-117203198-A Compounds as PU.1 inhibitors 浙江星浩澎博医药有限公司 2023-12-08 — — CN disclosed
EP-4247805-A1 COMPOUNDS AS PU. 1 INHIBITORS S-Infinity Pharmceuticals (CN) 2023-09-27 — — EP disclosed
WO-2022105825-A1 COMPOUNDS AS PU. 1 INHIBITORS PEKING UNIVERSITY (CN) 2022-05-27 — — WO disclosed
WO-2020132582-A1 STING AGONISTS AND USES THEREOF NIMBUS TITAN, INC. (US) 2020-06-25 — — WO disclosed
CN-106146416-B Nitrogen replaces 3- oxo -6- substituted-tetrahydro quinoxaline structural compounds, preparation method and its medical usage 河南大学 2019-02-19 — — CN disclosed
CN-106146416-A Nitrogen replaces 3 oxo 6 substituted-tetrahydro quinoxaline structural compounds, its preparation method and medical usage thereof 河南大学 2016-11-23 — — CN disclosed
CN-102933557-B Radiation protection immunomodulator compounds and method 彼得·麦卡勒姆癌症研究所 2016-08-03 — — CN disclosed
US-20080125358-A1 Methods for Chk2 inhibitor patient selection UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 2008-05-29 — — US disclosed
US-20080125358-A1 Methods for Chk2 inhibitor patient selection UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 2008-05-29 — — US disclosed
WO-2007133983-A2 2-AMINOBENZIMIDAZOLES FOR TREATING NEURODEGENERATIVE DISEASES PHARMACOPEIA, INC. (US) 2007-11-22 — — WO disclosed
EP-1658336-B1 MIXED CRYSTALS COMPRISING CI PIGMENT RED 170 DERIVATIVES CLARIANT PRODUKTE DEUTSCHLAND (DE) 2006-11-22 — — EP disclosed
EP-1658336-A1 MIXED CRYSTALS COMPRISING CI PIGMENT RED 170 DERIVATIVES Clariant Produkte (Deutschland) GmbH (DE) 2006-05-24 — — EP disclosed
WO-2005019346-A1 MIXED CRYSTALS COMPRISING CI PIGMENT RED 170 DERIVATIVES CLARIANT PRODUKTE (DEUTSCHLAND) GMBH (DE) 2005-03-03 — — WO disclosed
WO-2003099936-A1 NOVEL DERIVATIVES OF C.I. PIGMENT RED 170 CLARIANT GMBH (DE) 2003-12-04 — — WO disclosed
CN-1022830-C Preparation of benzamides FORDONAL SA (ES) 1993-11-24 — — CN disclosed
EP-0190524-B1 Industrial synthesis of N-[(1'-allyl-2'-pyrrolidinyl)methyl]-2-methoxy-4,5-azimido benzamide SOCIETE D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE (FR) 1991-03-06 — — EP disclosed
CN-86105972-A Novel benzamides — 1987-04-01 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018129-A1 COMPOUNDS AS PU. 1 INHIBITORS FLI1, MCL1, SP1 LMNA 2450/4885PARP1 724/4885TDP1 576/4885
US-20080125358-A1 Methods for Chk2 inhibitor patient selection CHEK2, CHEK1, TP53 LMNA 1664/4885PARP1 184/4885TDP1 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.